ZA200204225B - Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy. - Google Patents
Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy. Download PDFInfo
- Publication number
- ZA200204225B ZA200204225B ZA200204225A ZA200204225A ZA200204225B ZA 200204225 B ZA200204225 B ZA 200204225B ZA 200204225 A ZA200204225 A ZA 200204225A ZA 200204225 A ZA200204225 A ZA 200204225A ZA 200204225 B ZA200204225 B ZA 200204225B
- Authority
- ZA
- South Africa
- Prior art keywords
- active ingredient
- pharmaceutical preparation
- preparation according
- sheet
- ribbon
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title claims description 55
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 title claims description 26
- 230000036407 pain Effects 0.000 title claims description 12
- 238000002560 therapeutic procedure Methods 0.000 title claims description 12
- 210000000214 mouth Anatomy 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title description 22
- 206010012335 Dependence Diseases 0.000 title description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 38
- 229960002085 oxycodone Drugs 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 14
- 230000003232 mucoadhesive effect Effects 0.000 claims description 14
- 229940127240 opiate Drugs 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 210000002200 mouth mucosa Anatomy 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 10
- 239000007858 starting material Substances 0.000 claims description 7
- 239000000227 bioadhesive Substances 0.000 claims description 6
- 238000009256 replacement therapy Methods 0.000 claims description 6
- 206010013663 drug dependence Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000035699 permeability Effects 0.000 claims description 5
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 4
- 208000026251 Opioid-Related disease Diseases 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 201000006145 cocaine dependence Diseases 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 201000005040 opiate dependence Diseases 0.000 claims description 4
- 238000004080 punching Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229940126601 medicinal product Drugs 0.000 claims description 3
- 239000003401 opiate antagonist Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 claims description 2
- 230000036592 analgesia Effects 0.000 claims description 2
- 229960000263 levallorphan Drugs 0.000 claims description 2
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims description 2
- 229960000805 nalbuphine Drugs 0.000 claims description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 2
- 229960004127 naloxone Drugs 0.000 claims description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 2
- 229960003086 naltrexone Drugs 0.000 claims description 2
- 238000003856 thermoforming Methods 0.000 claims description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 4
- 229960003920 cocaine Drugs 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 238000010924 continuous production Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229920001169 thermoplastic Polymers 0.000 claims 1
- 239000002552 dosage form Substances 0.000 description 19
- 230000008901 benefit Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 235000012431 wafers Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical group C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000000071 blow moulding Methods 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical group C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 238000007757 hot melt coating Methods 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- CMDGQTVYVAKDNA-UHFFFAOYSA-N propane-1,2,3-triol;hydrate Chemical compound O.OCC(O)CO CMDGQTVYVAKDNA-UHFFFAOYSA-N 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19960154A DE19960154A1 (de) | 1999-12-14 | 1999-12-14 | Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200204225B true ZA200204225B (en) | 2003-03-03 |
Family
ID=7932547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200204225A ZA200204225B (en) | 1999-12-14 | 2002-05-28 | Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20040024003A1 (es) |
| EP (1) | EP1239847A1 (es) |
| JP (1) | JP2003516961A (es) |
| KR (1) | KR100597806B1 (es) |
| CN (1) | CN1407889A (es) |
| AR (1) | AR027902A1 (es) |
| AU (1) | AU781946B2 (es) |
| BR (1) | BR0016504A (es) |
| CA (1) | CA2393838A1 (es) |
| CZ (1) | CZ20022063A3 (es) |
| DE (1) | DE19960154A1 (es) |
| HU (1) | HUP0203733A2 (es) |
| IL (1) | IL150127A0 (es) |
| MX (1) | MXPA02005857A (es) |
| PL (1) | PL355816A1 (es) |
| RU (1) | RU2002115277A (es) |
| WO (1) | WO2001043728A1 (es) |
| ZA (1) | ZA200204225B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
| US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
| US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US7357891B2 (en) * | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| CN1655771A (zh) * | 2002-05-24 | 2005-08-17 | 艾克发照像有限责任公司 | 含有活性化合物且至少部分可降解的膜及其制备方法 |
| US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| BRPI0410956A (pt) * | 2003-05-28 | 2006-07-04 | Monosolrx Llc | pelìculas com base em óxido de polietileno e sistemas de liberação de droga feitos delas |
| DE10332160A1 (de) * | 2003-07-15 | 2005-02-03 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
| US7846940B2 (en) * | 2004-03-31 | 2010-12-07 | Cordis Corporation | Solution formulations of sirolimus and its analogs for CAD treatment |
| DE102005007859A1 (de) * | 2005-02-21 | 2006-08-24 | Lts Lohmann Therapie-Systeme Ag | Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen |
| CN1813740B (zh) * | 2005-11-22 | 2010-05-05 | 岳振江 | 一种含有盐酸纳洛酮的舌下膜剂及其制备方法 |
| BRPI0619806A2 (pt) * | 2005-12-13 | 2011-10-18 | Biodelivery Sciences Int Inc | dispositivo para fornecimento de fármacos transmucosal resistente ao abuso |
| DE102006027794A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Antihypertonie-Kombinationswafer |
| DE102006027790A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Typ-2-Diabetes Kombinations-Wafer |
| DE102006027793A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Opioid-Kombinations-Wafer |
| DE102006027791A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | AchE-NMDA-Kombinationswafer |
| DE102006027792A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Antidepressiva-Kombinations-Wafer |
| RS54764B1 (sr) * | 2006-07-21 | 2016-10-31 | Biodelivery Sciences Int Inc | Sredstvo za transmukozalnu isporuku sa povećanim nakupljanjem |
| US8420110B2 (en) * | 2008-03-31 | 2013-04-16 | Cordis Corporation | Drug coated expandable devices |
| CA2728912C (en) * | 2008-06-23 | 2018-04-10 | Biodelivery Sciences International, Inc. | Multidirectional mucosal delivery devices and methods of use |
| US20110269841A1 (en) * | 2010-05-03 | 2011-11-03 | Innoteq, Inc. | Thin film with methadone active ingredient |
| US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
| KR101944367B1 (ko) | 2011-08-18 | 2019-01-31 | 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 | 부프레노르핀 운반용 약물남용 억제 점막 부착 장치 |
| MX362217B (es) * | 2011-12-21 | 2019-01-09 | Biodelivery Sciences Int Inc | Dispositivos de administracion de farmacos por via transmucosal para uso en el alivio del dolor cronico. |
| US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
| WO2013171146A1 (en) * | 2012-05-15 | 2013-11-21 | Lts Lohmann Therapie-Systeme Ag | Oral film containing enteric release opiate resinate |
| KR20230137362A (ko) | 2016-05-05 | 2023-10-04 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US20200022974A1 (en) * | 2018-07-23 | 2020-01-23 | Trevi Therapeutics, Inc. | Treatment of chronic cough, breathlessness and dyspnea |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
| JPH02503672A (ja) * | 1987-06-01 | 1990-11-01 | ワーナー‐ランバート・コンパニー | 水性の系における浸透促進剤としての脂肪酸およびその短鎖エステル |
| US5236714A (en) * | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
| DE19642043A1 (de) * | 1995-10-23 | 1997-04-24 | Hexal Ag | Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht |
| DE19652188C2 (de) * | 1996-12-16 | 2002-02-14 | Lohmann Therapie Syst Lts | Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung |
| EP1021204B1 (en) * | 1997-09-26 | 2005-12-28 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| DE19923551A1 (de) * | 1999-05-21 | 2000-11-30 | Lohmann Therapie Syst Lts | Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht |
-
1999
- 1999-12-14 DE DE19960154A patent/DE19960154A1/de not_active Withdrawn
-
2000
- 2000-12-01 RU RU2002115277/15A patent/RU2002115277A/ru unknown
- 2000-12-01 MX MXPA02005857A patent/MXPA02005857A/es unknown
- 2000-12-01 WO PCT/EP2000/012093 patent/WO2001043728A1/de active IP Right Grant
- 2000-12-01 CA CA002393838A patent/CA2393838A1/en not_active Abandoned
- 2000-12-01 BR BR0016504-2A patent/BR0016504A/pt not_active Application Discontinuation
- 2000-12-01 PL PL00355816A patent/PL355816A1/xx not_active Application Discontinuation
- 2000-12-01 US US10/149,980 patent/US20040024003A1/en not_active Abandoned
- 2000-12-01 JP JP2001544667A patent/JP2003516961A/ja active Pending
- 2000-12-01 CZ CZ20022063A patent/CZ20022063A3/cs unknown
- 2000-12-01 IL IL15012700A patent/IL150127A0/xx unknown
- 2000-12-01 HU HU0203733A patent/HUP0203733A2/hu unknown
- 2000-12-01 EP EP00993377A patent/EP1239847A1/de not_active Withdrawn
- 2000-12-01 AU AU28392/01A patent/AU781946B2/en not_active Ceased
- 2000-12-01 KR KR1020027007565A patent/KR100597806B1/ko not_active IP Right Cessation
- 2000-12-01 CN CN00816787A patent/CN1407889A/zh active Pending
- 2000-12-13 AR ARP000106618A patent/AR027902A1/es unknown
-
2002
- 2002-05-28 ZA ZA200204225A patent/ZA200204225B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2839201A (en) | 2001-06-25 |
| EP1239847A1 (de) | 2002-09-18 |
| IL150127A0 (en) | 2002-12-01 |
| KR100597806B1 (ko) | 2006-07-10 |
| RU2002115277A (ru) | 2004-01-10 |
| BR0016504A (pt) | 2002-11-05 |
| AU781946B2 (en) | 2005-06-23 |
| MXPA02005857A (es) | 2002-10-23 |
| KR20020067544A (ko) | 2002-08-22 |
| PL355816A1 (en) | 2004-05-17 |
| JP2003516961A (ja) | 2003-05-20 |
| CN1407889A (zh) | 2003-04-02 |
| AR027902A1 (es) | 2003-04-16 |
| CZ20022063A3 (cs) | 2002-09-11 |
| WO2001043728A1 (de) | 2001-06-21 |
| US20040024003A1 (en) | 2004-02-05 |
| CA2393838A1 (en) | 2001-06-21 |
| DE19960154A1 (de) | 2001-07-12 |
| HUP0203733A2 (en) | 2003-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU781946B2 (en) | Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy | |
| AU741362B2 (en) | Flat medicament preparation for the application and release of buprenorphine or a pharmacologically comparable substance in the buccal cavity, and method of producing the same | |
| RU2316316C2 (ru) | Плоский или пластинчатый лекарственный препарат с исправленным вкусом | |
| AU2021201650A1 (en) | Abuse-resistant mucoadhesive devices for delivery of buprenorphine | |
| AU746373B2 (en) | Active substance carrier for releasing apomorphine into the buccal cavity | |
| KR930001804B1 (ko) | 첩부제 및 그의 제조방법 | |
| US20090110717A1 (en) | Transmucosal composition | |
| EA021051B1 (ru) | Биологически активный продукт | |
| CZ20014187A3 (cs) | Farmaceutický preparát s účinnou látkou diamorfin a jeho pouľití při způsobu oąetřování závislosti na opiátech | |
| MX2007011440A (es) | Tableta recubierta sublingual. | |
| Ponchel | Formulation of oral mucosal drug delivery systems for the systemic delivery of bioactive materials | |
| KR20060028767A (ko) | 다중층 구강분산성 정제 | |
| US20030153590A1 (en) | Method of treating alcoholism or alcohol abuse | |
| ZA200706640B (en) | Method for a treatment with a medicament combination and medicament combinations suitable for the same | |
| US20070190117A1 (en) | Buccal formulations of galanthamine and uses thereof | |
| WO2007103511A1 (en) | Multi-layer medical patch with impermeable center | |
| NZ622610B2 (en) | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |